Innocan Pharma Corporation

Recent News

  • Innocan Pharma CEO Iris Bincovich to Deliver a Speech at an Investor Gathering in Munich on October 29, 2021

    Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - October 28, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), is pleased to announce that CEO Iris Bincovich will embark on a 2 day trip on October 29-30 to Munich, Germany with the purpose of meeting investors and potential clients.Ms. Bincovich will attend an open Q&A session that will take place in the Novotel München Messe, Willy-Brandt-Platz 1, 81829 München. Please RVSP at info@innocanpharma.comMs. Bincovich will...

    2021-10-28 2:00 AM EDT
  • Innocan Reports of Presence of CBD in Mice's Brains 41 Days After Injection of CBD Using Innocan's Liposome Platform Technology

    Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - October 19, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), is pleased to announce the results of a recent study showed the presence of Cannabidiol (CBD) in mice's brains, 41 days after being injected with Innocan's CBD LPT (CBD-Loaded Liposome Platform Technology). In contrast, no CBD was demonstrated in mice's brains, 22 days following the injection of free CBD (without using Innocan's LPT delivery system).

    2021-10-19 4:00 PM EDT
  • Innocan Pharma Corporation Closes C$8.2 Million Private Placement with Institutional Investors

    Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - October 13, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), today announced that it has closed its previously announced private placement of the Company's common shares (a "Common Share" and, collectively, the "Common Shares") and warrants to purchase common shares ("Common Warrants") to institutional investors for aggregate gross proceeds to the Company of C$8,227,150 million (the "Private Placement"). Pursuant to the Private Placement, the Company has...

    2021-10-13 7:08 PM EDT
  • Innocan Pharma Corporation Announces C$8.2 Million Private Placement with Institutional Investors

    Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - October 8, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), today announced that it has entered into securities purchase agreements for a private placement of the Company's common shares (a "Common Share" and, collectively, the "Common Shares") and warrants to purchase common shares ("Common Warrants") to institutional investors for aggregate gross proceeds to the Company of approximately C$8.2 million (the "Private Placement"). Pursuant to the Private...

    2021-10-08 8:50 AM EDT
  • Innocan Pharma Announces the Filing of a PCT Patent Application for its CBD Delivery System Technology in 153 Countries

    Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - October 4, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), is pleased to announce that a new patent application has been filed for Innocan's CBD Delivery System Technology, alongside the existing LTP (CBD Loaded Liposomes) and CLX (CBD Loaded Exosomes). The new patent application discloses a unique and novel delivery system allowing the controlled release of CBD into the blood stream with improved pharmacokinetic (PK) performance....

    2021-10-04 4:12 PM EDT
  • Innocan Pharma Announces the Filing by Ramot at Tel Aviv University of an International Patent Application for its Unique Cannabinoids Loaded Exosome Delivery Platform (CLX)

    Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - September 24, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), hereby announces the filing by Ramot of a new patent application for a unique Cannabinoids exosome delivery platform - CLX, developed by Ramot and their researchers from Tel Aviv University. InnoCan holds worldwide exclusive option agreement to develop and commercialese the CLX and noticed Ramot on the intention to execute the option into full license agreement....

    2021-09-24 4:00 PM EDT
  • Innocan Pharma's CBD-Loaded Liposome Platform Technology Demonstrates a Prolonged Release of CBD in Large Animals

    Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - September 3, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), is pleased to announce that it has conducted a recent experimental study of its CBD-loaded liposome technology (LPT) on large animals that demonstrated a similar pharmacokinetic profile as was demonstrated in a previous small animal study. This result is expected to bring the Company closer to clinical trials in humans.Pharmacokinetics (PK) determines the profile of drug...

    2021-09-03 4:00 PM EDT
  • Innocan Pharma Received Proceeds of CAD $8.2M from the Exercise of Warrants since January 1, 2021

    Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - August 27, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") reports today, that since January 1st, 2021, it has received proceeds of approximately CAD $8.2M as a result of the exercise of approximately 32.9 Million previously issued common share purchase warrants and broker warrants. As a result, over 94% of Innocan's Warrants dated back to June 2020 and over 95% of its September 2019 warrants have...

    2021-08-27 4:00 PM EDT